Recent Advances in Optical Molecular Imaging and its Applications in Targeted Drug Delivery

Ma, Xibo; Hui, Hui; Shang, Wenting; Jia, Xiaohua; Yang, Xin; Tian, Jie

doi:10.2174/1389450116666150102112747

Cited by 10 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ideal clinical probe should exhibit a high target-to-background ratio to maximize in vivo image contrast. Additionally, it should possess characteristics such as high binding affinity, target-specific uptake and retention, rapid clearance from non-target tissues, stability and integrity in vivo, ease of preparation, and safe clinical use [ 69 , 72 ].…”

Section: Lung Cancer Targeting Probesmentioning

confidence: 99%

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Ekinci,

Magne,

Alencar

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

It is evident that radiolabeled drug delivery systems hold great promise in the field of lung cancer management. The combination of therapeutic agents with radiotracers not only allows for precise localization within lung tumors but also enables real-time monitoring of drug distribution. This approach has the potential to enhance targeted therapy and improve patient outcomes. The integration of advanced imaging modalities, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), has played a crucial role in the non-invasive tracking of radiolabeled drugs. These techniques provide valuable insights into drug pharmacokinetics, biodistribution, and tumor-targeting efficiency, offering clinicians the ability to personalize treatment regimens. The comprehensive analysis of preclinical and clinical studies presented in this review underscores the progress made in the field. The evidence suggests that radiolabeled drug delivery systems have the potential to revolutionize oncology by offering precise, targeted, and image-guided therapeutic interventions for lung cancer. This innovative approach not only enhances the effectiveness of treatment but also contributes to the development of personalized medicine strategies, tailoring interventions to the specific characteristics of each patient’s cancer. The ongoing research in this area holds promise for further advancements in lung cancer management, potentially leading to improved outcomes and quality of life for patients.

show abstract

Section: Lung Cancer Targeting Probesmentioning

confidence: 99%

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Ekinci,

Magne,

Alencar

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Genetically modified probe based bioluminescence imaging can be used to study the metabolic pathways, anticancer mechanisms as well as toxic side effects on living small animals in vivo (Tung et al, 2014; Liu et al, 2015; Horibe et al, 2018). Dynamic OI techniques can in vivo monitor the delivery process and whole-body distribution of drugs inside the body of living animals, which is great helpful for the study of drug metabolism and mechanism of action (Moriyama et al, 2008; Ma et al, 2015; Zhang et al, 2017). The application examples of the above OI technology in medicinal chemistry can be used in the study of NPs in the same way.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Harnessing the Power of Optical Microscopic and Macroscopic Imaging for Natural Products as Cancer Therapeutics

et al. 2019

View full text Add to dashboard Cite

Natural products (NPs) are an important source for new drug discovery over the past decades, which have been demonstrated to be effectively used in cancer prevention, treatment, and adjuvant therapy. Many methods, such as the genomic and metabolomic approaches, immunochemistry, mass spectrometry, and chromatography, have been used to study the effects of NPs on cancer as well as themselves. Because of the advantages in specificity, sensitivity, high throughput, and cost-effectiveness, optical imaging (OI) approaches, including optical microscopic imaging and macroscopic imaging techniques have also been applied in the studies of NPs. Optical microscopic imaging can observe NPs as cancer therapeutics at the cellular level and analyze its cytotoxicity and mechanism of action. Optical macroscopic imaging observes the distribution, metabolic pathway, and target lesions of NPs in vivo, and evaluates NPs as cancer therapeutics at the whole-body level in small living animals. This review focuses on the recent advances in NPs as cancer therapeutics, with particular emphasis on the powerful use of optical microscopic and macroscopic imaging techniques, including the studies of observation of ingestion by cells, anticancer mechanism, and in vivo delivery. Finally, we prospect the wider application and future potential of OI approaches in NPs as cancer therapeutics.

show abstract

“…Bioluminescence imaging (BLI) is a highly valuable modality with diverse applications in a wide range of biological models and systems. [74][75][76] BLI is a particularly useful tool for assessing and quantifying in vivo blood flow reduction following treatment with a VDA. 54,[76][77][78][79] In the current study MCF7 human breast cancer cells, which had been previously transfected stably to express the enzyme luciferase, as well as two fluorescent proteins, as designated by MCF7-luc-GFP-mCherry, were implanted in SCID mice, as described previously.…”

Section: Dynamic Bioluminescence Imagingmentioning

confidence: 99%

Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization

et al. 2016

View full text Add to dashboard Cite

The natural products colchicine and combretastatin A-4 (CA4) have been inspirational for the design and synthesis of structurally related analogues and spin-off compounds as inhibitors of tubulin polymerization. The discovery that a water-soluble phosphate prodrug salt of CA4 (referred to as CA4P) is capable of imparting profound and selective damage to tumor-associated blood vessels paved the way for the development of a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (VDAs). Combination of salient structural features associated with colchicine and CA4 led to the design and synthesis of a variety of fused aryl-cycloalkyl and aryl-heterocyclic compounds that function as inhibitors of tubulin polymerization. Prominent among these compounds is a benzosuberene analogue (referred to as KGP18), which demonstrates sub-nM cytotoxicity against human cancer cell lines and functions (when administered as a water-soluble prodrug salt) as a VDA in mouse models. Structure activity relationship considerations led to the evaluation of benzocyclooctyl [6,8 fused] and indene [6,5 fused] ring systems. Four benzocyclooctene and four indene analogues were prepared and evaluated biologically. Three of the benzocyclooctene analogues were active as inhibitors of tubulin polymerization (IC50 < 5 μM), and benzocyclooctene phenol 23 was comparable to KGP18 in terms of potency. The analogous indene-based compound 31 also functioned as an inhibitor of tubulin polymerization (IC50 = 11 μM) with reduced potency. The most potent inhibitor of tubulin polymerization from this group was benzocyclooctene analogue 23, and it was converted to its water-soluble prodrug salt 24 to assess its potential as a VDA. Preliminary in vivo studies, which utilized the MCF7-luc-GFP-mCherry breast tumor in a SCID mouse model, demonstrated that treatment with 24 (120 mg/kg) resulted in significant vascular shutdown, as evidenced by bioluminescence imaging at 4 h post administration, and that the effect continued at both 24 and 48 h. Contemporaneous studies with CA4P, a clinically relevant VDA, were carried out as a positive control.

show abstract

Recent Advances in Optical Molecular Imaging and its Applications in Targeted Drug Delivery

Cited by 10 publications

References 75 publications

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Harnessing the Power of Optical Microscopic and Macroscopic Imaging for Natural Products as Cancer Therapeutics

Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization

Contact Info

Product

Resources

About